Summary:
We report three patients with relapsed ovarian cancer who developed femoral head necrosis requiring endoprosthetic hip surgery 16–35 months after high-dose chemotherapy (HDC) with treosulfan (47 and 56 g/m2 body-surface area (BSA)) given as 3–25 h infusions and followed by autologous peripheral blood stem cell (PBSC) transplantation. One woman received two courses of single agent treosulfan while the other two patients received one course of high-dose treosulfan either preceded or followed by high-dose carboplatin, etoposide and cyclophosphamide. A total of 30 women with ovarian cancer were treated with HDC at our unit and 21 of them received treosulfan-containing regimens. Femoral head necrosis was not observed in patients either receiving conditioning regimens without treosulfan (n=9) or when the total treosulfan dose was given over 3 consecutive days (n=3) or in patients with a diagnosis other than ovarian cancer and treated with high-dose treosulfan (n=10). We conclude that women with relapsed ovarian cancer receiving HDC with excessive single-dose treosulfan might be at an increased risk of developing bone necrosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Stern JM, Sullivan KM, Ott SM et al. Bone density loss after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 257–264.
Ebeling PR, Thomas DM, Erbas B et al. Mechanism of bone loss following allogeneic and autologous hematopoietic stem cell transplantation. J Bone Miner Res 1999; 14: 342–350.
Weilbacher KN . Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2000; 6: 165–174.
Schulte C, Beelen DW, Schaefer UW et al. Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study. Osteoporosis Int 2000; 11: 344–353.
Lappe JM, Tinley ST . Prevention of osteoporosis in women treated for hereditary breast and ovarian cancer. Cancer 1998; 83: 830–834.
Gogas H, Fennelly D . Avascular necrosis following extensive chemotherapy and dexamethasone treatment in a patient with advanced ovarian cancer: case report and review of the literature. Gynecol Oncol 1996; 63: 379–381.
Scheulen ME, Hilger RA, Oberhoff C et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000; 6: 4209–4216.
Wagner HM, Baumgart J, Andreesen R et al. Dose-escalation of treosulfan in a high-dose-protocol: a classical alkylating agent new in high-dose combination chemotherapy. Proc ASCO 2000; 19: 54a (Abstr. 208).
Baynes RD, Dansey RD, Klein JL et al. A phase I trial of escalating treosulfan in combination with high-dose melphalan and dacarbazine (TMD) with peripheral blood progenitor cell transplant (PBPCT) in recurrent metastatic ovarian and breast cancer. Bone Marrow Transplant 2000; 26 (Suppl. 1) 33 (Abstr. P36).
Acknowledgements
We thank Dr C Poettgen, University of Essen Medical School, West German Cancer Center, Department of Radiotherapy for critical review of the radiation chart of patient 2, V.B.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bojko, P., Hilger, R., Ruehm, S. et al. Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 31, 487–491 (2003). https://doi.org/10.1038/sj.bmt.1703886
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703886